CN1931367A - Application of alginate in preparing medicine smell masking prepn - Google Patents
Application of alginate in preparing medicine smell masking prepn Download PDFInfo
- Publication number
- CN1931367A CN1931367A CN 200610041579 CN200610041579A CN1931367A CN 1931367 A CN1931367 A CN 1931367A CN 200610041579 CN200610041579 CN 200610041579 CN 200610041579 A CN200610041579 A CN 200610041579A CN 1931367 A CN1931367 A CN 1931367A
- Authority
- CN
- China
- Prior art keywords
- alginate
- taste
- application
- masking
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 75
- 235000010443 alginic acid Nutrition 0.000 title claims abstract description 29
- 229920000615 alginic acid Polymers 0.000 title claims abstract description 29
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 229940072056 alginate Drugs 0.000 title claims abstract description 27
- 230000000873 masking effect Effects 0.000 title claims abstract description 24
- 229940079593 drug Drugs 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 44
- 238000002360 preparation method Methods 0.000 claims abstract description 28
- 239000008187 granular material Substances 0.000 claims description 51
- 239000000648 calcium alginate Substances 0.000 claims description 33
- 229960002681 calcium alginate Drugs 0.000 claims description 33
- 235000019640 taste Nutrition 0.000 claims description 25
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 21
- 229940005550 sodium alginate Drugs 0.000 claims description 21
- 235000010413 sodium alginate Nutrition 0.000 claims description 21
- 239000000661 sodium alginate Substances 0.000 claims description 21
- 235000010410 calcium alginate Nutrition 0.000 claims description 10
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 10
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 claims description 9
- 229960004099 azithromycin Drugs 0.000 claims description 9
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 9
- 229960005224 roxithromycin Drugs 0.000 claims description 9
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical group [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 229930013930 alkaloid Natural products 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000057297 Pepsin A Human genes 0.000 claims description 5
- 108090000284 Pepsin A Proteins 0.000 claims description 5
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 5
- 229940111202 pepsin Drugs 0.000 claims description 5
- 238000004945 emulsification Methods 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 3
- 229910021645 metal ion Inorganic materials 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 229960002626 clarithromycin Drugs 0.000 claims description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 2
- 238000005354 coacervation Methods 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 235000010408 potassium alginate Nutrition 0.000 claims description 2
- 239000000737 potassium alginate Substances 0.000 claims description 2
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 claims description 2
- -1 suspensoid Substances 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 235000019634 flavors Nutrition 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 238000009776 industrial production Methods 0.000 abstract description 4
- 235000019658 bitter taste Nutrition 0.000 description 29
- 235000019645 odor Nutrition 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 238000004090 dissolution Methods 0.000 description 20
- 210000004051 gastric juice Anatomy 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 238000011835 investigation Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 240000002234 Allium sativum Species 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- FYBLWUVZITWWEZ-UHFFFAOYSA-N Cl.[Ca] Chemical compound Cl.[Ca] FYBLWUVZITWWEZ-UHFFFAOYSA-N 0.000 description 5
- 229940093265 berberine Drugs 0.000 description 5
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 5
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 235000004611 garlic Nutrition 0.000 description 5
- 239000010647 garlic oil Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000001779 taste bud Anatomy 0.000 description 5
- 235000019596 Masking bitterness Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000007863 gel particle Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000002308 calcification Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 241001474374 Blennius Species 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000008395 clarifying agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000000852 hydrogen donor Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
本发明公开了海藻酸盐在制备掩盖药物不良异味的制剂中的应用。该应用是将需要掩味的药物采用不溶性的海藻酸盐包裹,制成口服制剂。采用该应用制备的制剂能有效掩盖药物不良异味,本发明提供的实现该应用的方法简单易行,适合工业化大生产。The invention discloses the application of alginate in the preparation of preparations for masking bad smell of medicines. The application is to encapsulate the drug that needs to be taste-masked with insoluble alginate to make an oral preparation. The preparation prepared by using the application can effectively cover the bad smell of the medicine, and the method for realizing the application provided by the invention is simple and easy, and is suitable for large-scale industrial production.
Description
技术领域technical field
本发明属于医药领域,涉及海藻酸盐在制备掩盖药物不良异味的制剂中的应用。The invention belongs to the field of medicine and relates to the application of alginate in the preparation of preparations for masking the bad smell of medicines.
背景技术Background technique
很多的药物如多数无机盐、生物碱类、蛋白多肽类、大环内酯类抗生素、大蒜油等本身具有较强的苦味和异味,使得其在剂型开发及临床使用上受到了很大的限制。目前掩盖药物不良异味的方法一般来说有以下三种方法:(1)将药物结构进行改造,制备成无苦味的前体药物;(2)加入矫味剂、芳香剂、胶浆剂等掩盖苦味或麻痹味蕾,以达到掩味的目的;(3)采用制剂手段如包衣、包合、微囊等将药物与口腔粘膜上的味蕾隔开。Many drugs, such as most inorganic salts, alkaloids, protein polypeptides, macrolide antibiotics, garlic oil, etc., have strong bitterness and peculiar smell, which greatly restricts their formulation development and clinical use. . At present, there are generally three methods for covering the bad smell of drugs: (1) transforming the structure of the drug to prepare a non-bitter prodrug; (2) adding flavoring agents, fragrances, glues, etc. to cover Bitter or paralyzed taste buds, in order to achieve the purpose of taste masking; (3) use preparation methods such as coating, inclusion, microcapsules, etc. to separate the drug from the taste buds on the oral mucosa.
以下对现今制剂学上常用的两种掩盖药物苦味的方法进行比较:The following is a comparison of the two methods commonly used in pharmacy to mask the bitterness of drugs:
1、添加矫味剂:添加甜味剂、芳香剂、胶浆剂等辅料,用以麻痹味蕾或以甜味或香味掩盖苦味,此法需要加入较大量的矫味剂,方法虽然简单、但对较苦的药物作用有限,对于剂量较大的药物掩味效果也不佳。1. Adding flavoring agents: adding sweeteners, flavoring agents, mucilage and other auxiliary materials to numb the taste buds or cover up the bitterness with sweetness or fragrance. This method needs to add a large amount of flavoring agents. Although the method is simple, but It has limited effect on bitter drugs, and has poor taste-masking effect on drugs with large doses.
2、包衣:对药物粉末粒子进行包衣是掩盖苦味较有效的方法。目前常用有流化床包衣及相分离凝聚法。流化床包衣是常用的方法,一般需对粉末进行予处理,粉末太细可因静电作用凝集成团而影响包衣效果,而相分离凝聚法一般需要加入有机溶剂,工业化生产有一定难度。2. Coating: Coating the drug powder particles is a more effective method to mask the bitter taste. At present, fluidized bed coating and phase separation coagulation are commonly used. Fluidized bed coating is a commonly used method. Generally, the powder needs to be pre-treated. If the powder is too fine, it may agglomerate due to electrostatic interaction and affect the coating effect. The phase separation coagulation method generally requires the addition of organic solvents, which is difficult for industrial production. .
现有研究认为苦味药物分子中存在分子内氢键,即分子中有氢供给基和氢接受基,它们之间的距离(分子内氢键距离)在1.5A以内,使得药物疏水性增强。同时苦味药物分子中多含有其它疏水基团,这些基团易与苦味细胞的受体相结合(hydrophobicinteraction),对苦味细胞产生刺激作用,使人感觉到苦味。因此一般苦味物质的呈味阈值比酸、甜、咸味物质要低得多,即苦味物质容易吸附在苦味细胞受体膜上,使得其在很低的浓度下人体即能品尝到苦味。另外很多的苦味药物如生物碱类药物,在中性条件下大都带有正电荷,苦味受体膜表面带有负电荷,这样带正电荷的苦味物质就特别容易吸附于苦味受体膜上(electrostatic interaction),因此呈味阈值就非常低。Existing studies believe that there are intramolecular hydrogen bonds in bitter drug molecules, that is, there are hydrogen donor groups and hydrogen acceptor groups in the molecule, and the distance between them (intramolecular hydrogen bond distance) is within 1.5A, which enhances the hydrophobicity of the drug. At the same time, bitter drug molecules often contain other hydrophobic groups, and these groups are easy to combine with the receptors of bitter cells (hydrophobic interaction), which stimulates bitter cells and makes people feel bitter. Therefore, the taste threshold of general bitter substances is much lower than that of sour, sweet, and salty substances, that is, bitter substances are easily adsorbed on the bitter cell receptor membrane, so that the human body can taste bitterness at a very low concentration. In addition, many bitter drugs, such as alkaloids, are mostly positively charged under neutral conditions, and the surface of the bitter receptor membrane is negatively charged, so that positively charged bitter substances are particularly easily adsorbed on the bitter receptor membrane ( electrostatic interaction), so the taste threshold is very low.
海藻酸盐如海藻酸钠是一类从海带、马尾藻等藻类植物中提取出来的生物多糖类天然高分子化合物,是海藻细胞壁的主要成分,海藻酸经加工后,得到水溶性的海藻酸钠盐。海藻酸盐无毒、无刺激,且具有独特的理化性质和良好的生物相容性,被广泛应用于药物制剂、组织工程、临床治疗、细胞培养、食品加工等领域。大量研究表明海藻酸钠不仅是一种安全的食品添加剂,而且具有降脂、排除铅等重金属及抗肿瘤作用。在当今美国,海藻酸钠被誉为“奇妙的食品添加剂”;在日本被誉为“长寿食品”。目前海藻酸盐的需求量每年都在大幅增加,在各行业的应用也逐步扩大。Alginate such as sodium alginate is a kind of biological polysaccharide natural polymer compound extracted from algae plants such as kelp and sargassum. It is the main component of seaweed cell wall. After alginic acid is processed, water-soluble alginic acid is obtained sodium salt. Alginate is non-toxic, non-irritating, and has unique physical and chemical properties and good biocompatibility. It is widely used in pharmaceutical preparations, tissue engineering, clinical treatment, cell culture, food processing and other fields. A large number of studies have shown that sodium alginate is not only a safe food additive, but also has lipid-lowering, lead-free and anti-tumor effects. In the United States today, sodium alginate is known as a "wonderful food additive"; in Japan it is known as a "longevity food". At present, the demand for alginate is increasing substantially every year, and its application in various industries is gradually expanding.
海藻酸钠为白色或淡黄色粉末,其分子量高、呈线型、具有高水合性,在低浓度水溶液中就具有极高的粘度,分子中带有大量的羧基和羟基而带负电性,是很好的增稠剂、悬浮剂、填充剂、澄清剂、稳定剂及胶凝剂。海藻酸钠可与二价以上的金属离子络和交联,食品医药工业多用二价钙离子,生成的海藻酸钙具有水、酸不溶性,无毒且有足够的韧性强度。海藻酸钙凝胶可作为一种酶固定化、蛋白多肽类药物的口服给药以及缓控释给药的载体。海藻酸钙凝胶颗粒的制备方法主要有滴制法、浸渍法、反滴法、复合凝聚法等。而其中以滴制法操作最为简单,并且易于实现机械化工业的生产。Sodium alginate is a white or light yellow powder with high molecular weight, linear shape and high hydratability. It has extremely high viscosity in low-concentration aqueous solution. The molecule has a large number of carboxyl and hydroxyl groups and is negatively charged. Very good thickener, suspending agent, filler, clarifying agent, stabilizer and gelling agent. Sodium alginate can be complexed and cross-linked with metal ions above divalent, and divalent calcium ions are often used in the food and pharmaceutical industry. The resulting calcium alginate is insoluble in water and acid, non-toxic and has sufficient toughness and strength. Calcium alginate gel can be used as a carrier for enzyme immobilization, oral administration of protein and polypeptide drugs, and sustained and controlled release administration. The preparation methods of calcium alginate gel particles mainly include drop method, impregnation method, reverse drop method, composite coagulation method and so on. Among them, the drop method is the easiest to operate, and it is easy to realize the production of mechanized industry.
目前尚未有利用海藻酸盐对药物进行掩味的技术的报道。At present, there is no report on the technology of using alginate to mask the taste of drugs.
发明内容Contents of the invention
本发明的目的是在综合分析国内外掩盖药物苦味等不适性臭味的技术的基础上,提供了海藻酸盐在制备掩味剂中的应用,该应用的方法适合于工业化大生产。The purpose of the present invention is to provide the application of alginate in the preparation of taste-masking agent on the basis of comprehensive analysis of domestic and foreign technologies for masking unpleasant odors such as the bitter taste of medicines. The method of this application is suitable for large-scale industrial production.
本发明的目的是通过下列技术措施实现的:The purpose of the present invention is achieved through the following technical measures:
海藻酸盐在制备掩盖药物不良异味的制剂中的应用。Application of alginate in the preparation of preparations for masking bad odor of medicines.
所述的应用,该应用的方法是将需要掩味的药物采用不溶性的海藻酸盐包裹,制成口服制剂。Said application, the method of this application is to wrap the medicine that needs taste-masking with insoluble alginate to prepare oral preparation.
所述的应用,该方法是向可溶性的海藻酸盐溶液中加入需要掩味的药物,滴入含二价或二价以上金属离子的溶液充分反应,形成包裹了药物的不溶性海藻酸盐颗粒,过滤,干燥即可。Said application, the method is to add the drug that needs to be taste-masked to the soluble alginate solution, drop into the solution containing divalent or more than divalent metal ions to fully react, and form insoluble alginate particles wrapped with the drug, Filter and dry.
所述的应用,其中形成包裹了药物的不溶性海藻酸盐颗粒的方法采用滴制法、乳化法、浸渍法、反滴法、复合凝聚法、离心法、喷射法或喷雾冷凝法制备。Said application, wherein the method of forming the insoluble alginate particles wrapped with drugs is prepared by drop method, emulsification method, dipping method, reverse drop method, composite coacervation method, centrifugation method, spray method or spray condensation method.
所述的应用,其中可溶性的海藻酸盐是海藻酸钠、海藻酸钾中的一种或多种。Said application, wherein the soluble alginate is one or more of sodium alginate and potassium alginate.
所述的应用,其中不溶性的海藻酸盐是海藻酸钙。Said application, wherein the insoluble alginate is calcium alginate.
所述的应用,其中需要掩味的药物是大环内酯类抗生素、生物碱类药物、蛋白多肽类药物、具有刺激性异味的中药提取物。其中大环内酯类抗生素是阿齐霉素、罗红霉素或克拉霉素;生物碱类药物是盐酸小檗碱;蛋白多肽类药物是胃蛋白酶;具有强刺激性异味的中药提取物是大蒜油。In the above application, the drugs that need to be taste-masked are macrolide antibiotics, alkaloid drugs, protein polypeptide drugs, and traditional Chinese medicine extracts with pungent odors. Among them, macrolide antibiotics are azithromycin, roxithromycin or clarithromycin; alkaloid drugs are berberine hydrochloride; protein polypeptide drugs are pepsin; garlic oil.
所述的应用,其中口服制剂是颗粒剂、混悬剂、片剂、胶囊剂。Described application, wherein oral preparation is granule, suspension, tablet, capsule.
采用本发明成功地研制出罗红霉素、阿奇霉素、盐酸小檗碱、胃蛋白酶、大蒜油等掩味制剂。Taste-masking preparations such as roxithromycin, azithromycin, berberine hydrochloride, pepsin, garlic oil, etc. have been successfully developed by using the present invention.
按药物临床使用要求制成不同粒径颗粒后(载药量按药物占整个颗粒的重量百分比为5~95%、粒径:5μm~5mm),用于制备片剂、颗粒剂、混悬剂等各种口服剂型。According to the requirements of clinical use of drugs, particles of different particle sizes are made (drug loading is 5-95% by weight of the drug in the whole particle, particle size: 5μm-5mm), used to prepare tablets, granules, and suspensions and other oral dosage forms.
本发明的有益效果:Beneficial effects of the present invention:
1、本发明利用海藻酸盐可以包裹药物形成水、酸不溶性的海藻酸钙颗粒,将之应用于苦味等不良异味药物载药,一方面海藻酸盐分子中含的大量负电性基团可起到屏蔽苦味药物的正电荷,使之较少与味蕾的接触;另一方面海藻酸盐钙化后包裹药物,且由于海藻酸钙不溶于水,药物在口腔内的溶解量大大降低,可以减少药物与味蕾的接触,从而有效发挥掩味的作用。1. The present invention uses alginate to wrap drugs to form water- and acid-insoluble calcium alginate particles, which are applied to drug loading of bad smell drugs such as bitter taste. On the one hand, a large number of negatively charged groups contained in alginate molecules can act as To shield the positive charge of the bitter drug, so that it has less contact with the taste buds; on the other hand, the alginate is calcified to wrap the drug, and because the calcium alginate is insoluble in water, the amount of the drug dissolved in the oral cavity is greatly reduced, which can reduce the amount of the drug. The contact with the taste buds can effectively play the role of taste masking.
2、本发明提供的实现该应用的方法简单易行,适于工业化大生产。2. The method for realizing the application provided by the present invention is simple and feasible, and is suitable for large-scale industrial production.
具体实施方式Detailed ways
下面将描述本发明的几个实施例,但本发明的内容完全不限于此。Several embodiments of the present invention will be described below, but the content of the present invention is not limited thereto at all.
海藻酸钠样品来源:Sodium alginate sample source:
海藻酸钠样品1(220cps)、2(430cps)、3(530cps)-青岛胶南明月海藻工业有限公司提供;Sodium alginate samples 1 (220cps), 2 (430cps), 3 (530cps) - provided by Qingdao Jiaonan Mingyue Seaweed Industry Co., Ltd.;
海藻酸钠样品4(型号LVCR,粘度50cps)、5(型号DMB,粘度300cps)、6(型号HVCR,粘度400cps)、7(型号Kecosol,粘度1300cps)-国际特品提供(UK ISP Alginate Ltd)。Sodium alginate samples 4 (model LVCR, viscosity 50cps), 5 (model DMB, viscosity 300cps), 6 (model HVCR, viscosity 400cps), 7 (model Kecosol, viscosity 1300cps) - provided by International Special Products (UK ISP Alginate Ltd) .
以下实施例中溶出度及掩味效果采用下列方法:Dissolution and taste-masking effect adopt the following methods in the following examples:
溶出度:按2005版药典规定方法转篮法测定其所载药物溶出度,45分钟溶出在70%以上。Dissolution rate: According to the method specified in the 2005 edition of the Pharmacopoeia, the dissolution rate of the drug contained in it was measured by the basket method, and the dissolution rate was above 70% in 45 minutes.
掩味效果:将制备的掩味颗粒加入适量温水,一定时间点取样测定药物在水中的溶出浓度,是否在苦味浓度之下,30min后摇匀口服应无苦味或不适性臭味。Taste-masking effect: add the prepared taste-masking granules to an appropriate amount of warm water, take samples at a certain time point to measure the dissolution concentration of the drug in water, whether it is below the bitterness concentration, shake well after 30 minutes and take it orally, there should be no bitterness or unpleasant odor.
实施例1:阿奇霉素-海藻酸钙颗粒的制备,及苦味掩盖效果的考察。Example 1: Preparation of azithromycin-calcium alginate granules, and investigation of bitterness masking effect.
【滴制法制备阿奇霉素-海藻酸钙掩味颗粒】【Preparation of azithromycin-calcium alginate taste-masking granules by drop method】
将阿奇霉素混悬于1.5%海藻酸钠溶液中,在常温下用针头将混悬液滴入2%氯化钙溶液中,即可形成凝胶颗粒,将之钙化1小时后取出,过滤冲洗后干燥,得到的干燥颗粒待用。Suspend azithromycin in 1.5% sodium alginate solution, drop the suspension into 2% calcium chloride solution with a needle at room temperature to form gel particles, calcify it for 1 hour, take it out, filter and rinse Dry, and the resulting dry granules are ready for use.
【阿奇霉素苦味浓度的确定】【Determination of the Bitterness Concentration of Azithromycin】
将阿奇霉素制备成10%的浓度,加水稀释成不同浓度后,按浓到稀和稀到浓的不同顺序反复多人品尝,确定无苦味浓度。经测定,阿齐霉素的无苦味浓度为≤150μg/ml。Prepare azithromycin at a concentration of 10%, add water to dilute it to different concentrations, and repeatedly taste it with multiple people in different orders from thick to thin and thin to thick to determine the concentration without bitterness. After determination, the non-bitter taste concentration of azithromycin is ≤150 μg/ml.
【苦味掩盖效果考察】【Investigation on the masking effect of bitter taste】
将制备得到的干燥颗粒300mg(含药250mg)置于50ml去离子水中,5mmin,10min,30min取样,检测药物在水中的浓度并品尝30min后颗粒在口腔中的苦味,同时按照中国药典的方法测定药物在人工胃液(0.1M盐酸液)中的溶出度,见表1。Place 300mg of the prepared dry granules (containing 250mg of medicine) in 50ml of deionized water, take samples for 5mmin, 10min, and 30min, detect the concentration of the drug in the water and taste the bitter taste of the granules in the oral cavity after 30min, and measure according to the method of Chinese Pharmacopoeia See Table 1 for the dissolution rate of medicine in artificial gastric juice (0.1M hydrochloric acid solution).
表1阿齐霉素-海藻酸钙掩味颗粒在水中和人工胃液中的溶出情况。
观察以上实验数据,结果表明30min内,阿奇霉素从掩味颗粒中释放含量均远远低于苦味浓度,并且其在水中释放的药量与海藻酸钠型号、粘度等并无直接联系,在人工胃液中45min可溶出药物大于90%以上,说明其溶出度合格。说明运用滴制法制备得到的海藻酸钙含药凝胶颗粒具有良好的苦味掩蔽效果,并且能在胃内较快的溶出。Observing the above experimental data, the results show that within 30 minutes, the amount of azithromycin released from the taste-masking granules is far lower than the concentration of bitterness, and the amount of azithromycin released in water is not directly related to the type and viscosity of sodium alginate. The drug that can be dissolved in 45 minutes is more than 90%, indicating that its dissolution rate is qualified. It shows that the calcium alginate drug-containing gel particles prepared by the dropping method have good bitterness masking effect, and can dissolve quickly in the stomach.
实施例2:罗红霉素-海藻酸钙掩味颗粒的制备,及苦味掩盖效果的考察Example 2: Preparation of Roxithromycin-Calcium Alginate Taste-masking Granules, and Investigation of Bitter Taste Masking Effect
【滴制法制备罗红霉素-海藻酸钙掩味颗粒】【Preparation of roxithromycin-calcium alginate taste-masking granules by drop method】
将罗红霉素混悬于1.5%海藻酸钠溶液中(海藻酸钠与药物重量比为1∶6),常温下用针头将混悬液滴入2%氯化钙溶液中即可形成凝胶颗粒,钙化1小时后取出,过滤冲洗后干燥,得干燥颗粒备用。Suspend roxithromycin in 1.5% sodium alginate solution (the weight ratio of sodium alginate to drug is 1:6), drop the suspension into 2% calcium chloride solution with a needle at room temperature to form a gel Glue granules were taken out after calcification for 1 hour, filtered, rinsed and dried to obtain dry granules for later use.
【罗红霉素苦味浓度的确定】【Determination of Roxithromycin Bitterness Concentration】
将罗红霉素制备成10%的浓度,加水稀释成不同浓度后,按浓到稀和稀到浓的不同顺序反复多人品尝,确定无苦味浓度。经测定,罗红霉素的无苦味浓度为≤60μg/ml。Prepare roxithromycin at a concentration of 10%, add water to dilute it to different concentrations, and repeatedly taste it with multiple people in different orders from thick to thin and thin to thick to determine the concentration without bitterness. After determination, the non-bitter taste concentration of roxithromycin is ≤60 μg/ml.
【苦味掩盖效果考察】【Investigation on the masking effect of bitter taste】
将制备得到的干燥颗粒180mg(含药150mg)置于50ml去离子水中,5mmin,10min,30min取样,检测药物在水中的浓度并品尝30min后颗粒在口腔中的苦味,同时按照中国药典的方法测定药物在人工胃液(0.1M盐酸液)中的溶出度,见表2Place 180mg of the prepared dry granules (containing 150mg of medicine) in 50ml of deionized water, take samples for 5mmin, 10min, and 30min, detect the concentration of the drug in the water and taste the bitter taste of the granules in the oral cavity after 30min, and measure according to the method of the Chinese Pharmacopoeia The dissolution rate of medicine in artificial gastric juice (0.1M hydrochloric acid solution), see Table 2
表2罗红霉素-海藻酸钙掩味颗粒在水中和人工胃液中的溶出情况
观察以上实验数据,结果表明30min内,罗红霉素从掩味颗粒中释放含量均远远低于苦味浓度,并且其在水中释放的药量与海藻酸钠型号、粘度等并无直接联系,在人工胃液中45min可溶出药物大于90%以上。说明运用滴制法制备得到的海藻酸钙含药凝胶颗粒具有良好的苦味掩蔽效果,并且能在胃内较快的溶出。Observing the above experimental data, the results show that within 30 minutes, the release content of roxithromycin from the taste-masking granules is far lower than the bitterness concentration, and the amount of roxithromycin released in water is not directly related to the type and viscosity of sodium alginate. In the artificial gastric juice 45min, the drug can be dissolved more than 90%. It shows that the calcium alginate drug-containing gel particles prepared by the dropping method have good bitterness masking effect, and can dissolve quickly in the stomach.
实施例3:盐酸小檗碱-海藻酸钙掩味颗粒的制备,及苦味掩盖效果的考察Example 3: Preparation of Berberine Hydrochloride-Calcium Alginate Taste-masking Granules, and Investigation of Bitter Taste Masking Effect
【乳化法制备盐酸小檗碱-海藻酸钙掩味颗粒】[Preparation of berberine hydrochloride-calcium alginate taste-masking granules by emulsification method]
将盐酸小檗碱混悬于2.0%海藻酸钠溶液中(海藻酸钠与药物重量比为1∶1),常温下将混悬液加入到含有适量吐温80的液体石蜡中(混悬液与液体石蜡体积比为1∶4),磁力搅拌30min后,滴入2ml、2%氯化钙溶液,钙化3小时,静置1h将沉淀物取出,过滤冲洗去表面的油状物,干燥,得干燥颗粒备用。Suspend berberine hydrochloride in 2.0% sodium alginate solution (the weight ratio of sodium alginate and drug is 1:1), and add the suspension into liquid paraffin containing an appropriate amount of Tween 80 at normal temperature (suspension The volume ratio to liquid paraffin is 1:4), after magnetic stirring for 30 minutes, 2ml, 2% calcium chloride solution was added dropwise, calcified for 3 hours, the precipitate was taken out after standing for 1 hour, the oil on the surface was washed by filtration, and dried to obtain Dry granules for later use.
【盐酸小檗碱苦味浓度的确定】【Determination of bitterness concentration of berberine hydrochloride】
将盐酸小檗碱制备成10%的浓度,加水稀释成不同浓度后,按浓到稀和稀到浓的不同顺序反复多人品尝,确定无苦味浓度。经测定,盐酸小檗碱的无苦味浓度为≤50μg/ml。Prepare berberine hydrochloride at a concentration of 10%, add water to dilute it to different concentrations, and taste it repeatedly in different orders from thick to thin and thin to thick to determine the concentration without bitterness. It has been determined that the non-bitter taste concentration of berberine hydrochloride is ≤50 μg/ml.
【苦味掩盖效果考察】【Investigation on the masking effect of bitter taste】
将制备得到的干燥颗粒200mg(含药100mg)置于50ml去离子水中,5mmin,10min,30min取样,检测药物在水中的浓度并品尝30min后颗粒在口腔中的苦味,同时按照中国药典的方法测定药物在人工胃液(0.1M盐酸液)中的溶出度,见表2Put 200mg of the prepared dry granules (containing 100mg of medicine) in 50ml of deionized water, take samples for 5mmin, 10min, and 30min, detect the concentration of the drug in the water and taste the bitter taste of the granules in the oral cavity after 30min, and measure according to the method of Chinese Pharmacopoeia The dissolution rate of medicine in artificial gastric juice (0.1M hydrochloric acid solution), see Table 2
表3盐酸小檗碱-海藻酸钙掩味颗粒在水中和人工胃液中的溶出情况
观察以上实验数据,结果表明30min内,盐酸小檗碱从掩味颗粒中释放含量均远远低于苦味浓度,在人工胃液中45min可溶出药物大于70%以上。说明运用乳化法制备得到的海藻酸钙含药掩味颗粒具有良好的苦味掩蔽效果,并且能在胃内较快的溶出。Observing the above experimental data, the results show that within 30 minutes, the release content of berberine hydrochloride from the taste-masking granules is far lower than the bitterness concentration, and the drug can be dissolved in the artificial gastric juice for 45 minutes is greater than 70%. It shows that the calcium alginate-containing drug-masking granules prepared by the emulsification method have a good bitterness masking effect and can dissolve quickly in the stomach.
实施例4:胃蛋白酶-海藻酸钙掩味颗粒的制备,及腥味掩盖效果的考察Example 4: Preparation of Pepsin-Calcium Alginate Taste-masking Granules, and Investigation of Odor Masking Effect
【喷射法制备胃蛋白酶-海藻酸钙掩味颗粒】【Preparation of pepsin-calcium alginate taste-masking granules by spraying method】
将胃蛋白酶混悬于1.5%海藻酸钠溶液中(海藻酸钠与药物重量比为1∶6),采用喷射装置,在常温下将混悬液喷入2%氯化钙溶液中即可形成颗粒,钙化1小时后取出,过滤冲洗后干燥,得干燥颗粒备用。Suspend pepsin in 1.5% sodium alginate solution (the weight ratio of sodium alginate to drug is 1:6), use a spraying device to spray the suspension into 2% calcium chloride solution at room temperature to form The granules were taken out after 1 hour of calcification, filtered, rinsed and then dried to obtain dry granules for later use.
【腥味掩盖效果考察】【Investigation on the masking effect of fishy smell】
将制备得到的颗粒250mg(含药200mg)置于50ml去离子水中,5mmin,10min,30min取样,品尝30min后颗粒在口腔中的腥味度,见表4所示。Place 250 mg of the prepared granules (containing 200 mg of medicine) in 50 ml of deionized water, take samples for 5 min, 10 min, and 30 min, and taste the fishy taste of the granules in the oral cavity after 30 min, as shown in Table 4.
表4胃蛋白酶-海藻酸钙掩味颗粒在水中的溶出情况
观察以上实验数据,结果表明,胃蛋白酶颗粒剂在15min内品尝不到腥味,但在30min有稍许腥味。表明颗粒剂在十五分钟内口服无腥味,具有较好的掩味效果。Observing the above experimental data, the results showed that the pepsin granule could not taste fishy smell within 15 minutes, but had a little fishy smell within 30 minutes. It shows that the granule has no fishy smell when taken orally within 15 minutes, and has a good taste-masking effect.
实施例5:大蒜油-海藻酸钙掩味颗粒的制备,及臭味掩盖效果的考察Example 5: Preparation of Garlic Oil-Calcium Alginate Taste-masking Granules, and Investigation of Odor Masking Effect
【离心法制备大蒜油-海藻酸钙掩味颗粒】[Preparation of garlic oil-calcium alginate taste-masking granules by centrifugation]
将大蒜油混悬于2.0%海藻酸钠溶液中(海藻酸钠与大蒜油重量比为1∶2),常温下采用离心法,将混悬液甩入2%氯化钙溶液中即可形成颗粒,钙化1小时后取出,过滤冲洗后干燥,得干燥颗粒备用。Suspend garlic oil in 2.0% sodium alginate solution (the weight ratio of sodium alginate to garlic oil is 1:2), use centrifugation at room temperature, and throw the suspension into 2% calcium chloride solution to form The granules were taken out after 1 hour of calcification, filtered, rinsed and then dried to obtain dry granules for later use.
【腥味掩盖效果考察】【Investigation on the masking effect of fishy smell】
将制备得到的干燥颗粒500mg(含药300mg)置于50ml去离子水中,5mmin,10min,30min取样,品尝30min后颗粒在口腔中的臭味,见表5所示。Place 500 mg of the prepared dry granules (containing 300 mg of medicine) in 50 ml of deionized water, take samples for 5 min, 10 min, and 30 min, and taste the odor of the granules in the oral cavity after 30 min, as shown in Table 5.
表5大蒜油-海藻酸钙掩味颗粒在水中的溶出情况。
观察以上实验数据,结果表明,大蒜油-海藻酸钙掩味颗粒在30min内品尝不到臭味。表明颗粒剂在三十分钟内口服无臭味,具有较好的掩味效果。Observing the above experimental data, the results show that the garlic oil-calcium alginate taste-masking particles cannot taste the odor within 30 minutes. It shows that the granule has no odor when taken orally within 30 minutes, and has a good taste-masking effect.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610041579 CN1931367A (en) | 2006-09-15 | 2006-09-15 | Application of alginate in preparing medicine smell masking prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610041579 CN1931367A (en) | 2006-09-15 | 2006-09-15 | Application of alginate in preparing medicine smell masking prepn |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1931367A true CN1931367A (en) | 2007-03-21 |
Family
ID=37877489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610041579 Pending CN1931367A (en) | 2006-09-15 | 2006-09-15 | Application of alginate in preparing medicine smell masking prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1931367A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105535147A (en) * | 2015-12-30 | 2016-05-04 | 广西壮族自治区花红药业股份有限公司 | Taste-improved Gegen Qinlian pills and preparation method |
| CN109105499A (en) * | 2018-08-22 | 2019-01-01 | 山东省农业科学院农业资源与环境研究所 | A kind of milk tea powder and preparation method thereof containing lucidum spore powder |
| KR20210033433A (en) * | 2019-09-18 | 2021-03-26 | 정원구 | Drug suspension for companion animals and method for manufacturing the same |
| CN114532463A (en) * | 2022-03-08 | 2022-05-27 | 渤海水产股份有限公司 | Seaweed compound, preparation method and application thereof, and fish culture feed |
-
2006
- 2006-09-15 CN CN 200610041579 patent/CN1931367A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105535147A (en) * | 2015-12-30 | 2016-05-04 | 广西壮族自治区花红药业股份有限公司 | Taste-improved Gegen Qinlian pills and preparation method |
| CN109105499A (en) * | 2018-08-22 | 2019-01-01 | 山东省农业科学院农业资源与环境研究所 | A kind of milk tea powder and preparation method thereof containing lucidum spore powder |
| CN109105499B (en) * | 2018-08-22 | 2021-07-20 | 山东省农业科学院农业资源与环境研究所 | A kind of milk tea powder containing Ganoderma lucidum spore powder and preparation method thereof |
| KR20210033433A (en) * | 2019-09-18 | 2021-03-26 | 정원구 | Drug suspension for companion animals and method for manufacturing the same |
| KR102530032B1 (en) * | 2019-09-18 | 2023-05-09 | 정원구 | Drug suspension for companion animals and method for manufacturing the same |
| CN114532463A (en) * | 2022-03-08 | 2022-05-27 | 渤海水产股份有限公司 | Seaweed compound, preparation method and application thereof, and fish culture feed |
| CN114532463B (en) * | 2022-03-08 | 2023-12-22 | 渤海水产股份有限公司 | Seaweed compound, preparation method and application thereof, and fish-farming feed |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1606472A (en) | Adsorbent for phosphoric acid | |
| CN100337661C (en) | Application of snake grape plants and its extracts in the preparation of medicines and health products | |
| CN106924750B (en) | Somalutide oral particle preparation and preparation method thereof | |
| CN101317832B (en) | Oral administration nano-drug administration system of resveratrol | |
| CN1931367A (en) | Application of alginate in preparing medicine smell masking prepn | |
| CN1465285A (en) | Lead-expelling health food and preparation method thereof | |
| CN111718974A (en) | Application of mung bean peptide in preparation of medicine for promoting lead excretion, active peptide and application thereof | |
| CN100427096C (en) | A kind of preparation method of salidroside nano liposome suspension | |
| CN1217669C (en) | Naringin used in preparing medicine for curing acute and chronic bronchitis | |
| CN1857302A (en) | Medicine for treating hyperphosphatemia and its preparing method | |
| CN104645334B (en) | N acetylcysteine activated carbon composites and its preparation method and application | |
| CN103251557B (en) | A kind of Felodipine nano suspension and preparation method thereof | |
| CN108904519A (en) | Hericium erinaceus Polysaccharides are in the purposes prepared in the drug for treating colitis and include its pharmaceutical composition | |
| Arulanandraj et al. | Nanotechnological approach to enhance the stability and bioavailability of the herbal drug “murva” | |
| CN1278676C (en) | Curcumin injection and method for preparing the same | |
| CN1739686A (en) | Chinese medicine injection for clearing away heat and toxic matter and its prepn process | |
| CN1762341A (en) | Salvianolic acid compound for treating cardiovascular and cerebrovascular disease and liver disease, and application thereof | |
| CN1911235A (en) | Colon target prepn. contg. 5-aminosalicylic acid, and its prepn. method | |
| CN1915324A (en) | Pediatric Fupi preparation and preparation method thereof | |
| CN119606889A (en) | Composite polysaccharide microspheres capable of releasing NO and preparation method and application thereof | |
| CN1840539A (en) | Petrel saponin and its preparation method and use | |
| CN1616024A (en) | Shengmai powder injection and shengmai chewing tablet and its producing process | |
| CN120360952A (en) | A stable and efficient doxycycline hydrochloride soluble powder and preparation method thereof | |
| WO2016015691A1 (en) | A pharmaceutical composition having antibacterial and virucidal effects | |
| CN1830458A (en) | New uses of Tribulus terrestris extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20070321 |